Stevanato Group S.p.A. (STVN) Form 6-K — Nov 3, 2026
Stevanato Group reported Q3 2026 revenue of €326.1 million, up 8% (8% organic), with net profit up 16% to €41.8 million and adjusted EBITDA margin expanding 150 basis points to 27.2%. Biopharmaceutical and Diagnostic Solutions grew 11% organically to €294.0 million, offsetting a 12% decline in the Engineering Segment; GLP-1 therapies represented roughly 17-18% of revenue while non-GLP-1 biologics grew over 30%.
Key figures
- Eps
- 0.15
- Revenue
- 326100000
- Guidance
- FY2026 revenue €1.260-1.280 billion, adjusted EBITDA €335.0-345.2 million, adjusted diluted EPS €0.60-0.62
- Net Income
- 41800000
- Total Debt
- 353700000
- Revenue Yoy
- 8%
- Cash Position
- 114900000
- Capex q3
- €44.8 million
- Bds revenue
- €294.0 million (+10%, +11% organic)
- Gross margin q3
- 29.1% (-10 bps)
- Free cash flow q3
- €21.7 million
- Adjusted ebitda q3
- €88.8 million (+14%)
- Glp1 revenue share
- 17-18% of total revenue
- Nine month revenue
- €901.6 million
- Engineering revenue
- €32.0 million (-12%)
- Operating cash flow q3
- €57.6 million
- Organic revenue growth
- 8%
- Adjusted diluted eps q3
- €0.16 (+14%)
- Adjusted ebitda margin q3
- 27.2% (+150 bps)
- Non glp1 biologics growth
- over 30%
- High value solutions revenue
- €149.4 million (46% of total)
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.